NMIBC chemotherapy intravesical

NMIBC chemotherapy hyperthermia

Bladder Cancer Checkpoint Inhibitors Chemotherapy Immunotherapy Urothelial Cancer

Adjuvant Chemotherapy Bladder-sparing Chemoradiation Enhanced Recovery after Surgery Muscle-invasive Bladder Cancer Neoadjuvant Chemotherapy Radical Cystectomy Transurethral Resection of Bladder Tumor Trimodal Urothelial Carcinoma of Bladder Variant Histology

Bladder Cancer Chemotherapy Cystectomy Immune Checkpoint Inhibitors

Humans Photosensitizing Agents/therapeutic use Neoplasm Residual Neoplasm Recurrence Local/prevention & control *Photochemotherapy/methods Randomized Controlled Trials as Topic *Urinary Bladder Neoplasms/drug therapy/surgery/diagnosis Aminolevulinic Acid/therapeutic use Cystoscopy/methods Cystoscopy Fluorescent cystoscopy Hexaminolevulinate Meta-analysis Nonmuscle invasive bladder cancer Urinary bladder neoplasms conflicts of interest in the manuscript and during the submission process. This manuscript has not been published and is not under consideration for publication elsewhere.

Humans *Carcinoma Transitional Cell *Urinary Bladder Neoplasms/pathology Retrospective Studies BCG Vaccine/therapeutic use Administration Intravesical Adjuvants Immunologic *Organ Transplantation Neoplasm Invasiveness Neoplasm Recurrence Local/pathology Bcg Bladder cancer Chemotherapy Mitomycin Transplanted patients

Bladder cancer Intra-arterial chemotherapy Intravesical chemotherapy Recurrence Survival

bladder cancer gemcitabine intravesical chemotherapy

Aged Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Carcinoma Transitional Cell/*drug therapy/*pathology Female Humans Immune Checkpoint Inhibitors/*therapeutic use Liver Neoplasms/secondary Male Middle Aged Survival Analysis Urinary Bladder Neoplasms/*drug therapy/*pathology bladder cancer immune checkpoint inhibitors immunotherapy meta-analysis urothelial carcinoma

Administration Intravesical Combined Modality Therapy Cystectomy/*methods Humans Neoplasm Recurrence Local/*epidemiology Network Meta-Analysis Randomized Controlled Trials as Topic Urethra Urinary Bladder Neoplasms/*diagnostic imaging/drug therapy/epidemiology/*surgery #BladderCancer #blcsm #uroonc blue-light cystoscopy hexaminolevulinic acid narrow band imaging non-muscle-invasive urothelial carcinoma photodynamic diagnosis single immediate intravesical chemotherapy

Humans Carboplatin/therapeutic use *Carcinoma Transitional Cell/drug therapy *Urinary Bladder Neoplasms Carboplatin Cisplatin Immune checkpoint inhibitors Platinum-based chemotherapy Urothelial carcinoma

bladder cancer checkpoint inhibitors chemotherapy immunotherapy radical cystectomy design of the study in the collection analyses or interpretation of data in the writing of the manuscript or in the decision to publish the results.

Humans *Neoplasm Recurrence Local/drug therapy *Urinary Bladder Neoplasms/pathology Infusions Intra-Arterial Chemotherapy Adjuvant Adverse Reactions bladder cancer intra-arterial chemotherapy meta-analysis prognosis

Bladder cancer neoadjuvant chemotherapy radical cystectomy systematic review variant histology urothelial cancer

Administration Intravesical *Carcinoma Transitional Cell/pathology Epirubicin/therapeutic use Female Humans Male Mitomycin/therapeutic use Neoplasm Recurrence Local Randomized Controlled Trials as Topic *Urinary Bladder Neoplasms/pathology Intravesical Chemotherapy Non-muscle Invasive Bladder Cancer Turb

adjuvant chemotherapy bladder cancer cystectomy

Antineoplastic Combined Chemotherapy Protocols/therapeutic use *Carcinoma Transitional Cell/pathology Cisplatin/therapeutic use Cystectomy Humans Muscles/pathology Neoadjuvant Therapy Neoplasm Invasiveness *Urinary Bladder Neoplasms/pathology Bladder cancer Muscle-invasive Urothelial from MSD and BMS and Speaker and Other from AstraZecena. BPV reports Advisory Board Speaker and Other from Astellas Roche BMS and Merk-Pfizer Advisory Board and Other from Ipsen Advisory Board and Speaker from EUSA and MSD and Advisory Board from Sanofi. IPF report Advisory Board Speaker and Other from Pfizer Speaker and Other from Ipsen and Roche Advisory Board from EUSA and BMS and Speaker from Novartis and MSD. OFC reports Advisory Board and Speaker from Ipsen and Astellas Advisory Board from BMS and Pfizer-Merck and Speaker from AstraZeneca. AGA has received research funding from Astellas travel grants from Astellas Jansen Sanofi BMS Roche Pfizer and Ipsen and honoraria for speaker engagements advisory boards and continuous medical education from Janssen Astellas Sanofi Bayer Roche Ipsen BMS MSD Pfizer Eusa Pharma Eisai and AstraZeneca. JAA reports honoraria from Astellas Pfizer and BMS conulting or advisory role from Pfizer Astellas Janssen-Cilag MSD Oncology BMS Merck AstraZeneca Bayer and Eisai and Research Funding from BMS. RMB SVE CCD and MDS have nothing to disclose.

Aminolevulinic Acid China Cystoscopy Humans Neoplasm Recurrence Local *Photochemotherapy/methods Photosensitizing Agents *Urinary Bladder Neoplasms/diagnosis 5-aminolevulinic acid Bladder cancer Fluorescent cystoscopy Hexylaminolevulinate

Antineoplastic Combined Chemotherapy Protocols/adverse effects Bayes Theorem *Carcinoma Transitional Cell/drug therapy/surgery Humans Network Meta-Analysis *Urinary Bladder Neoplasms/drug therapy/surgery Ici Pd-1 Pd-l1 adjuvant therapy chemotherapy urothelial carcinoma